Intensive-care company Getinge reported on Wednesday the receipt of US Food & Drug Administration's (FDA) 510(k) market clearance for a new software version of the Servo-u and Servo-n mechanical ventilator platform in aid of patients with severe respiratory diseases.
According to the World Health Organisation, respiratory diseases make up five of the 30 most common causes of death. Lung diseases and ARDS (Acute Respiratory Distress Syndrome) play a significant role. Virtually all patients with ARDS require mechanical ventilation to assist the lungs with oxygenation and provide time to heal.
The company's upgraded software includes Servo Compass and High Flow therapy as well as additional advancements for ventilation therapy compliant with the ARDSnet protocol 3 and goal directed lung protective ventilation for all patient categories with the inclusion of measurement of driving pressure. The new features include volume control with decelerating flow, enhanced alarm management, streamlined setup for modes of ventilation and context based guidance for ease of use.
Getinge expects the new software and related modules to be launched in the US at the end of April 2019.
Servo Compass visualises volume and pressure in relation to set targets in invasive modes, alerting clinicians to potentially changing conditions and allowing them to intervene with appropriate therapy. High Flow therapy reduces the patient's work of breathing, improving comfort and tolerance. The goal is to enable clinicians to wean patients from the ventilator and promote lung protective ventilation.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review